Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Revlimid (lenalidomide) - Important Safety Information from Celgene Europe Limited as approved by the HPRA (Nov 2016)
Notice type:
3rd Party Publications
Date:
08/11/2016
Problem Or Issue:
Important Safety Information communication from Celgene Europe Limited: Revlimid (lenalidomide) - New important advice regarding viral reactivation.
Important Safety Information - Revlimid (lenalidomide)
« Back
Date Printed: 18/05/2024